Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 11 - 20 of about 181   

Articles published

AZN 4,543.67
price chart
Why Pfizer Inc. (PFE) May Not Bid For AstraZeneca plc (ADR) (AZN) Again?
Pfizer's main objective behind AstraZeneca plc (ADR) (NYSE:AZN) was to gain access to its cancer drugs pipeline. However, failure pushed Pfizer to look for alternatives.
Related articles »  
JPMorgan Chase & Co. Reaffirms "Underweight" Rating for AstraZeneca plc (AZN)
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email ...
AstraZeneca plc Given Underweight Rating at JPMorgan Chase & Co. (AZN)  Ticker Report
AstraZeneca plc Receives Hold Rating from Beaufort Securities (AZN)  WKRB News
Related articles »  
AstraZeneca plc (ADR) (AZN) CEO Pascal Soriot Banking On Accelerated ...
AstraZeneca plc (ADR) (NYSE:AZN) was considered somewhat of a dying flame two years ago, according to its CEO Pascal Soriot, but now the company is set for high paced development in the pharmaceutical industry with several essential new drugs ...
Hot Stocks: AstraZeneca plc (ADR) (NYSE:AZN), Regulus Therapeutics Inc ...  Techsonian (press release)
Related articles »  
AstraZeneca plc Receives Buy Rating from Liberum Capital (NYSE:AZN)
AstraZeneca plc (ADR) logo Liberum Capital reiterated their buy rating on shares of AstraZeneca plc (NYSE:AZN) in a research report released on Wednesday morning.
AstraZeneca plc Target of Unusually Large Options Trading (AZN)  sleekmoney
Related articles »  
Pfizer Inc. (PFE), AstraZeneca plc (ADR) (AZN) Round 2; START
The pharmaceutical industry was the focus of intense debate earlier this year owing to potential merger between Pfizer Inc. (NYSE:PFE) and AstraZeneca plc (ADR) (NYSE:AZN). With the six month cooling period coming to its close, the question that looms ...
Weekly Analysts' Ratings Changes for AstraZeneca plc (AZN)  Ticker Report
AstraZeneca plc Earns Hold Rating from Baader Helvea (AZN)  Intercooler
Related articles »  
AstraZeneca plc (AZN) Caught In Nexium Pay-For-Delay Trial With Ranbaxy ...
Speculations as to whether Pfizer Inc. (NYSE:PFE) would approach AstraZeneca plc (ADR) (NYSE:AZN) with a renewed bid have been keeping the spotlight away from the legal crosshairs the British pharmaceutical is stuck in regarding its key drug Nexium.
AstraZeneca plc (AZN) - Investment Analysts' Weekly Ratings Changes
AstraZeneca plc (NYSE:AZN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.05 earnings per share for the quarter, beating the analysts' consensus estimate of $1.04 by $0.01.
AstraZeneca plc's "Buy" Rating Reaffirmed at Citigroup Inc. (AZN)  Ticker Report
AstraZeneca plc Earns Neutral Rating from Credit Suisse (AZN)  Mideast Time
Related articles »  
AstraZeneca (AZN) Wins Pay-For-Delay Deal
AstraZeneca plc (ADR)(NYSE:AZN) landed itself a court victory Friday, saving itself from paying up billions of dollars. The company won a US court case that accused it of paying manufacturers to delay the launch of cheap generic medicines.
AstraZeneca, Ranbaxy prevail in Nexium antitrust trial  Hindu Business Line
Related articles »  
Friday Hot News: Constellation Brands Inc. (STZ), AstraZeneca PLC (AZN ...
AstraZeneca PLC (AZN) of the Drug Manufacturers - Major sector closed out the day yesterday at $72.11, a gain of 2.74% and return on investment of 9.00% trading at a volume of 1,194,767 shares.
Related articles »  
AstraZeneca plc Given "Buy" Rating at Liberum Capital (AZN)
AstraZeneca plc (NYSE:AZN)'s stock had its �buy� rating reissued by investment analysts at Liberum Capital in a note issued to investors on Wednesday.